OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 122,808 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 121.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,596 shares of the company’s stock after purchasing an additional 122,808 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Teva Pharmaceutical Industries were worth $3,747,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TEVA. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $41,000. Sound Income Strategies LLC grew its stake in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares during the last quarter. MAI Capital Management raised its holdings in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after acquiring an additional 697 shares during the period. Brooklyn Investment Group boosted its holdings in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after acquiring an additional 4,014 shares during the period. Finally, CWM LLC lifted its holdings in Teva Pharmaceutical Industries by 18.1% during the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after purchasing an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the transaction, the director owned 495,000 shares of the company’s stock, valued at $11,934,450. This represents a 28.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.49% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TEVA shares. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Scotiabank assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus target price of $30.25.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $29.74 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a market capitalization of $34.10 billion, a PE ratio of 49.56, a price-to-earnings-growth ratio of 1.53 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $29.80. The stock’s 50-day simple moving average is $23.03 and its 200 day simple moving average is $19.44.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.